Alicia Brunssen1, Annika Waldmann2, Nora Eisemann2, Alexander Katalinic3. 1. Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany. Electronic address: alicia.brunssen@uksh.de. 2. Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany. 3. Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany; Institute for Cancer Epidemiology, University of Lübeck, Lübeck, Germany.
Abstract
BACKGROUND: Benefits of skin cancer screening remain controversial. OBJECTIVE: We sought to update evidence on the impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence, mortality, stage-specific incidence, and interval cancers after negative screening. METHODS: We searched MEDLINE and EMBASE for studies published in English or German between January 1, 2005, and February 4, 2015. Two reviewers independently performed study selection, data extraction, and critical appraisal. Results were described in a narrative synthesis. RESULTS: Of 2066 records identified in databases and 10 records found by manual search, we included 15 articles. Overall, evidence suggests that with implementation of skin cancer screening, incidence of in situ and invasive skin cancer increased; increasing rates of thin and decreasing rates of thick melanoma were observed. After cessation of screening, invasive melanoma incidence decreased. A significant melanoma mortality reduction was shown in a German study; 2 other studies observed fewer deaths than expected. No study on interval cancers was identified. LIMITATIONS: Publication bias cannot be ruled out. Most studies are limited because of their ecological design. CONCLUSION: Large ecological studies, a cohort study, a case-control study, and a survey indicate benefits of skin cancer screening, but the evidence level is very low.
BACKGROUND: Benefits of skin cancer screening remain controversial. OBJECTIVE: We sought to update evidence on the impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence, mortality, stage-specific incidence, and interval cancers after negative screening. METHODS: We searched MEDLINE and EMBASE for studies published in English or German between January 1, 2005, and February 4, 2015. Two reviewers independently performed study selection, data extraction, and critical appraisal. Results were described in a narrative synthesis. RESULTS: Of 2066 records identified in databases and 10 records found by manual search, we included 15 articles. Overall, evidence suggests that with implementation of skin cancer screening, incidence of in situ and invasive skin cancer increased; increasing rates of thin and decreasing rates of thick melanoma were observed. After cessation of screening, invasive melanoma incidence decreased. A significant melanoma mortality reduction was shown in a German study; 2 other studies observed fewer deaths than expected. No study on interval cancers was identified. LIMITATIONS: Publication bias cannot be ruled out. Most studies are limited because of their ecological design. CONCLUSION: Large ecological studies, a cohort study, a case-control study, and a survey indicate benefits of skin cancer screening, but the evidence level is very low.
Authors: Clio Dessinioti; Alan C Geller; Aravella Stergiopoulou; Susan M Swetter; Eszter Baltas; Jonathan E Mayer; Timothy M Johnson; John Talaganis; Myrto Trakatelli; Dimitrios Tsoutsos; Gerasimos Tsourouflis; Alexander J Stratigos Journal: JAMA Dermatol Date: 2018-05-01 Impact factor: 10.282
Authors: Alisa M Goldstein; Margaret A Tucker; Michael R Sargen; Ruth M Pfeiffer; David E Elder; Xiaohong R Yang Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04 Impact factor: 4.090
Authors: Michael B Atkins; Clara Curiel-Lewandrowski; David E Fisher; Susan M Swetter; Hensin Tsao; Julio A Aguirre-Ghiso; Maria S Soengas; Ashani T Weeraratna; Keith T Flaherty; Meenhard Herlyn; Jeffrey A Sosman; Hussein A Tawbi; Anna C Pavlick; Pamela B Cassidy; Sunandana Chandra; Paul B Chapman; Adil Daud; Zeynep Eroglu; Laura K Ferris; Bernard A Fox; Jeffrey E Gershenwald; Geoffrey T Gibney; Douglas Grossman; Brent A Hanks; Douglas Hanniford; Eva Hernando; Joanne M Jeter; Douglas B Johnson; Samir N Khleif; John M Kirkwood; Sancy A Leachman; Darren Mays; Kelly C Nelson; Vernon K Sondak; Ryan J Sullivan; Glenn Merlino Journal: Clin Cancer Res Date: 2021-01-07 Impact factor: 13.801
Authors: Katie Mills; Jon Emery; Rebecca Lantaff; Michael Radford; Merel Pannebakker; Per Hall; Nigel Burrows; Kate Williams; Catherine L Saunders; Peter Murchie; Fiona M Walter Journal: BMJ Open Date: 2017-11-28 Impact factor: 2.692
Authors: Jens Hoebel; Lars E Kroll; Julia Fiebig; Thomas Lampert; Alexander Katalinic; Benjamin Barnes; Klaus Kraywinkel Journal: Front Oncol Date: 2018-09-25 Impact factor: 6.244